DOCSLIB.ORG

Health Statistics for the Nordic Countries

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Health Statistics for the Nordic Countries 2014 Health Statistics for the Nordic Countries Nordic Medico-Statistical Committee 102:2014 Health Statistics in the Nordic Countries 2014 Health Statistics in the Nordic Countries 2014 Members of the Editorial Committee for Health Statistics in the Nordic Countries Denmark Linda Saabye Kongerslev Statens Serum Institut Faroe Islands Chief Medical Officer Høgni Debes Joensen National Board of Health Branch Manager Terji Petersen National Board of Health Greenland Chief Medical Officer Flemming Kleist Stenz National Board of Health Finland Research Professor Mika Gissler National Institute for Health and Wel- fare THL Åland Axel Hansson Landskapsläkare Ålands landskapsregering Iceland Consultant Margrét Björk Svavarsdóttir Ministry of Welfare Norway Statistical Advisor Jorun Ramm Statistics Norway Sweden Researcher Ingalill Paulsson Lütz The National Board of Health and Wel- fare NOMESCO’s Editor: secretariat Jesper Munk Marcussen Layout and graphics: Lene Kokholm Translation: Executive Office, Christina Gry Paulsen © Nordic Medico-Statistical Committee Copenhagen 2014 ISBN 978–87-89702-86-5 ISSN 2245-9626 Contents Contents Preface ....................................................................... 8 Chapter I Organization of the Health Services ..................................... 9 Introduction ....................................................................................... 9 1.1 Current and future changes in the health services .................................. 10 1.2 Organization and responsibility for the health sector .............................. 19 1.3 Supervision of health services and health care personnel .......................... 29 1.4 Complaints about health services and health care personnel ..................... 31 Chapter II Population and Fertility .................................................. 33 Introduction ...................................................................................... 33 2.1 Population and population trends ...................................................... 34 2.2 Fertility, births, infant mortality and contraception ................................ 42 Chapter III Morbidity, Medical Treatment, Accidents and Medicinal Products ........................................................ 51 Introduction ...................................................................................... 51 3.1 Diseases related to lifestyle ............................................................. 52 3.2 Cancer ...................................................................................... 62 3.3 Immunization Schedules .................................................................. 74 3.4 Discharges, bed days, average length of stay and patients treated ............... 76 3.5 Surgical procedures ..................................................................... 103 3.6 Accidents and self-inflicted injury ................................................... 125 3.7 Development in consumption of medicinal products ............................. 126 5 Contents Chapter IV Mortality and Causes of Death ......................................... 156 Chapter V Resources ................................................................ 181 Introduction .................................................................................... 181 5.1 Financing of health services ........................................................... 182 5.2 User charges for health care services per 1 January 2014 ........................ 184 Medical visits ................................................................................... 184 Reimbursement for Pharmaceuticals ........................................................ 187 Treatment in hospitals ......................................................................... 190 Reimbursement for dental treatment ....................................................... 192 Maximum user charges ......................................................................... 195 5.3 Health care expenditure ............................................................... 198 5.4 Health care personnel ................................................................. 202 5.5 Capacity and Services in the Hospital Sector ....................................... 208 Appendix Further information ..................................................... 209 NOMESCO's Publications since 2000 ................................... 214 6 Contents Symbols used in the tables: Figures not available or too unreliable for use .. Information not applicable . Less than half of the unit used 0.0/0 Nothing to report (value nil) - Five year averages are always written as 20xx-xy Two year averages are always written as 20xx/xy Data are always calculated in relation to the respective age groups 7 Preface Preface The 2014 version of NOMESCO’s Health Statistics in the Nordic Countries is now avail- able. Since 1966, NOMESCO has worked to promote and publish comparable Nordic health statistics. As a permanent part of the work, this annual publication is published with the latest data in the health area. Health Statistics in the Nordic Countries presents data concerning population trends, illness, hospital treatment and causes of death. Furthermore, a description of the health sector in the Nordic countries, its structure and resources is provided. Health Statistics in the Nordic Countries consequently provides an annual cross section of the health care areas in the Nordic countries. This version comprises the latest available data as per the summer of 2014. The lat- est data year may consequently be 2013 or 2012. Previous versions are available at www.nowbase.org, where also our database and more specialized publications from projects carried out by NOMESCO can be found. As from 2011, the publication will no longer be designated by the latest data year, but instead by the year of production. Therefore, the title is Health Statistics in the Nordic Countries 2014. Nordic Medico-Statistical Committee (NOMESCO), January 2015 8 Organization of health services Chapter 1 Organization of Health Services Introduction In the Nordic countries, the health care sector is mainly a public matter. All the countries have well-established systems of primary health care. In addition to general medical practitioner services, preventive services have been established for mothers and infants, as well as school health care and dental care for children and young people. Preventive occupational health services and general measures for the protection of the environment have also been established in all the countries. The countries generally have well-developed hospital sectors with highly advanced specialist treatment. Specialist medical treatment is also offered outside hospitals. The health services are provided in accordance with legislation, and they are largely financed by public spending or through statutory health insurance schemes. Some patient charges are, however, payable for pharmaceutical products and to some extent also for treatment. Salary or cash allowances are payable to employees during illness. Self-employed people have the possibility of insuring themselves against illness. 9 Organization of health services 1.1 Current and future changes in the health care sector DENMARK: Introduction to diagnostic evaluation and treatment guarantee of psychiatric pa- tients In 2013, the Danish government proposed a bill regarding a change of the Health Act and the legislation regarding the access to appeals and compensations within the health care system. This Act introduces a diagnostic evaluation right of two months from September 1st 2014, which is reduced to one month (equalling the rights in all other parts of the health care system) from September 1st 2015. At the same time, a differentiated treatment right is introduced from September 1st 2014: One month at serious illness and two months at less serious illness. The diagnostic evaluation and treatment right will apply to both children and adults. The bill was passed in June 2014. Visibility reform The Government, KL - Kommunernes Landsforening (Local Government DK) and Dans- ke Regioner (Danish Regions) have with the Financial Agreement for 2014 agreed up- on a visibility reform. The purpose is to use health data in a more proactive way, which will propel the progress in the health care system and motivate the health care staff to create improvements in the treatment of patients. The reform is the framework for a continuous process with new initiatives and actions for a better use of data in the development of quality in the health area, which will be launched dur- ing the coming years. Over a period of four years, 32 million DKK has been allocated to this reform. Increased quality and diminishment of coercion in psychiatry In connection with the National Budget 2014, The Government and the political par- ties Venstre and Det Konservative Folkeparti have agreed to set a target about dimin- ishing by 50 percent the use of coercion in psychiatry. 50 million DKK has been allo- cated for the establishment of collaborations with the Regions about reduction of coercion. Furthermore, 100 million DKK has been set aside to improve the physical environment within psychiatric health care. New and improved treatment for children with cancer In connection with the National Budget 2014, The Government and the political par- ties Venstre and Det Konservative Folkeparti have strengthened cancer treatment with a state grant of 275 million DKK for the establishment
Load more

Recommended publications
  • Urea Adducts of the Esters of Stearic Acid
    University of the Pacific Scholarly Commons University of the Pacific Theses and Dissertations Graduate School 1952 Urea adducts of the esters of stearic acid Paul Elliott Greene University of the Pacific Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds Part of the Chemistry Commons Recommended Citation Greene, Paul Elliott. (1952). Urea adducts of the esters of stearic acid. University of the Pacific, Thesis. https://scholarlycommons.pacific.edu/uop_etds/1186 This Thesis is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been accepted for inclusion in University of the Pacific Theses and Dissertations by an authorized administrator of Scholarly Commons. For more information, please contact [email protected]. I': UREA,, ADDUCTS OF THE :ESTERS OF S'rEARIC ACID A Thesis Presented to Tb.~ Faculty of the Department of Chemistry College of the Pacific In Partial Fulfillment of the Requi:r>ements for the Degree Master of A:rts by Paul Elliott Greene... June 1952 ACKNOt~L1i:DGE~4ENT Appreciation is expressed to th.e faculty members of the Chemistry Department of the College of the Paciflc and ospecially to Dr. H;merson Cobb for the gu.idance and criticism given to the writer during this p~>r:i.od of' study. TABLE OF CONTENTS PAGE Urea and urea complexes .. • .. • • .. • .. • • • • • • 1 Adducts of' hydrocl.'ll1bon der1 vati ves • • • • • * • Similar molecular complexes • • • • • • • • • Structure cf ut.. ea £'.d.ducts • • . .. .. • 7 --------App-lioat:Lon-of_:ux~ee.-a.dd"u.cts-~--~-·--~-~-·-·-.. -·-·-· 11.---- P:r•eparati.on of intermedi.ates • • • • • • • • • • • 14 Purif:toation of ste:Htr:to ao:td .
    [Show full text]
  • UREA/AMMONIA (Rapid)
    www.megazyme.com UREA/AMMONIA (Rapid) ASSAY PROCEDURE K-URAMR 04/20 (For the rapid assay of urea and ammonia in all samples, including grape juice and wine) (*50 Assays of each per Kit) * The number of tests per kit can be doubled if all volumes are halved © Megazyme 2020 INTRODUCTION: Urea and ammonia are widely occurring natural compounds. As urea is the most abundant organic solute in urine, and ammonia is produced as a consequence of microbial protein catabolism, these analytes serve as reliable quality indicators for food products such as fruit juice, milk, cheese, meat and seafood. Ammonium carbonate is used as a leaven in baked goods such as quick breads, cookies and muffins. Unlike some other kits, this kit benefits from the use of a glutamate dehydrogenase that is not inhibited by tannins found in, for example, grape juice and wine. In the wine industry, ammonia determination is important in the calculation of yeast available nitrogen (YAN). YAN is comprised of three highly variable components, free ammonium ions, primary amino nitrogen (from free amino acids) and the contribution from the sidechain of L-arginine.1 For the most accurate determination of YAN, all three components should be quantified, and this is possible using Megazyme’s L-Arginine/Urea/Ammonia Kit (K-LARGE) and NOPA Kit (K-PANOPA). Urea determination can be important in preventing the formation of the known carcinogen ethyl carbamate (EC) in finished wine. PRINCIPLE: Urea is hydrolysed to ammonia (NH3) and carbon dioxide (CO2) by the enzyme urease (1). (urease) (1) Urea + H2O 2NH3 + CO2 In the presence of glutamate dehydrogenase (GlDH) and reduced nicotinamide-adenine dinucleotide phosphate (NADPH), ammonia (as + ammonium ions; NH4 ) reacts with 2-oxoglutarate to form L-glutamic acid and NADP+ (2).
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Amino Acid Catabolism: Urea Cycle the Urea Bi-Cycle Two Issues
    BI/CH 422/622 OUTLINE: OUTLINE: Protein Degradation (Catabolism) Digestion Amino-Acid Degradation Inside of cells Urea Cycle – dealing with the nitrogen Protein turnover Ubiquitin Feeding the Urea Cycle Activation-E1 Glucose-Alanine Cycle Conjugation-E2 Free Ammonia Ligation-E3 Proteosome Glutamine Amino-Acid Degradation Glutamate dehydrogenase Ammonia Overall energetics free Dealing with the carbon transamination-mechanism to know Seven Families Urea Cycle – dealing with the nitrogen 1. ADENQ 5 Steps 2. RPH Carbamoyl-phosphate synthetase oxidase Ornithine transcarbamylase one-carbon metabolism Arginino-succinate synthetase THF Arginino-succinase SAM Arginase 3. GSC Energetics PLP uses Urea Bi-cycle 4. MT – one carbon metabolism 5. FY – oxidases Amino Acid Catabolism: Urea Cycle The Urea Bi-Cycle Two issues: 1) What to do with the fumarate? 2) What are the sources of the free ammonia? a-ketoglutarate a-amino acid Aspartate transaminase transaminase a-keto acid Glutamate 1 Amino Acid Catabolism: Urea Cycle The Glucose-Alanine Cycle • Vigorously working muscles operate nearly anaerobically and rely on glycolysis for energy. a-Keto acids • Glycolysis yields pyruvate. – If not eliminated (converted to acetyl- CoA), lactic acid will build up. • If amino acids have become a fuel source, this lactate is converted back to pyruvate, then converted to alanine for transport into the liver. Excess Glutamate is Metabolized in the Mitochondria of Hepatocytes Amino Acid Catabolism: Urea Cycle Excess glutamine is processed in the intestines, kidneys, and liver. (deaminating) (N,Q,H,S,T,G,M,W) OAA à Asp Glutamine Synthetase This costs another ATP, bringing it closer to 5 (N,Q,H,S,T,G,M,W) 29 N 2 Amino Acid Catabolism: Urea Cycle Excess glutamine is processed in the intestines, kidneys, and liver.
    [Show full text]
  • Catalytic Carbonylation of Amines And
    CATALYTIC CARBONYLATION OF AMINES AND DIAMINES AS AN ALTERNATIVE TO PHOSGENE DERIVATIVES: APPLICATION TO SYNTHESES OF THE CORE STRUCTURE OF DMP 323 AND DMP 450 AND OTHER FUNCTIONALIZED UREAS By KEISHA-GAY HYLTON A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2004 Copyright 2004 by Keisha-Gay Hylton Dedicated to my father Alvest Hylton; he never lived to celebrate any of my achievements but he is never forgotten. ACKNOWLEDGMENTS A number of special individuals have contributed to my success. I thank my mother, for her never-ending support of my dreams; and my grandmother, for instilling integrity, and for her encouragement. Special thanks go to my husband Nemanja. He is my confidant, my best friend, and the love of my life. I thank him for providing a listening ear when I needed to “discuss” my reactions; and for his support throughout these 5 years. To my advisor (Dr. Lisa McElwee-White), I express my gratitude for all she has taught me over the last 4 years. She has shaped me into the chemist I am today, and has provided a positive role model for me. I am eternally grateful. I, of course, could never forget to mention my group members. I give special mention to Corey Anthony, for all the free coffee and toaster strudels; and for helping to keep the homesickness at bay. I thank Daniel for all the good gossip and lessons about France. I thank Yue Zhang for carbonylation discussions, and lessons about China.
    [Show full text]
  • On the Effects of Urea on the Molecular Structure and Activity of Various
    The Journal of Biochemistry, Vol. 58, No. 1, 1965 Effects of Urea on the Activity and Structure of Yeast Alcohol Dehydrogenase By TAKAHISA OHTA* and YASUYUEI OGURA (From the Department of Biophysics and Biochemistry, Faculty of Science, University of Tokyo, Bunkyo-ku, Tokyo) (Received for publication, March 29, 1965) There have been many reports (1-8) on (9) and K lot z (10). However, to interprete the effects of urea on the molecular structure the mechanism of inhibition by urea on enzyme and activity of various enzymes. Most reactions, further investigations are necessary enzymes (1-4) are known to be inhibited by since few have covered both kinetics of the en low concentrations of urea which do not zymatic reaction and physicochemical analysis denature their protein. The mode of inhibi of the structural changes of the enzyme protein. tion of urea on various enzyme reactions has In this paper, the effects of urea upon yeast been studied kinetically by R a j a g o p a l a n, alcohol dehydrogenase [EC 1. 1. 1. 1, Alcohol: Fridovich and Handler (3) and also NAD oxidoreductase (yeast)] have been studi by Chase's group (6-8) using rather low ed, focusing attention on the relationship be concentrations of urea. The inhibition by tween the structure of the enzyme molecule urea of various enzymes, such as xanthine and its catalytic activity. oxidase [EC 1.2.3.2], muscle lactate dehydro EXPERIMENTAL genase [EC 1. 1. 1. 27] (3) and kidney aldose mutarotase [EC 5.1.3.3] (6) has been reported Materials-Yeast alcohol dehydrogenase was prepar to be reversible and competitive for the sub ed from fresh baker's yeast* by the following pro strate.
    [Show full text]
  • NIH Public Access Author Manuscript Bioorg Med Chem Lett
    NIH Public Access Author Manuscript Bioorg Med Chem Lett. Author manuscript; available in PMC 2013 September 15. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Bioorg Med Chem Lett. 2012 September 15; 22(18): 5889–5892. doi:10.1016/j.bmcl.2012.07.074. Biologically Active Ester Derivatives as Potent Inhibitors of the Soluble Epoxide Hydrolase In-Hae Kima,b, Kosuke Nishia,b, Takeo Kasagamia,c, Christophe Morisseaua, Jun-Yan Liua, Hsing-Ju Tsaia, and Bruce D. Hammocka,* aDepartment of Entomology and UC Davis Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, California 95616, USA Abstract Substituted ureas with a carboxylic acid ester as a secondary pharmacophore are potent soluble epoxide hydrolase (sEH) inhibitors. Although the ester substituent imparts better physical properties, such compounds are quickly metabolized to the corresponding less potent acids. Toward producing biologically active ester compounds, a series of esters were prepared and evaluated for potency on the human enzyme, stability in human liver microsomes, and physical properties. Modifications around the ester function enhanced in vitro metabolic stability of the ester inhibitors up to 32-fold without a decrease in inhibition potency. Further, several compounds had improved physical properties. Keywords sEH; sEH inhibitors; substituted urea-ester derivatives; metabolic stability Epoxyeicosatrienoic acids (EETs), which are metabolites of arachidonic acid by cytochrome P450 epoxygenases,
    [Show full text]
  • Effect of Thiol Molecular Structure on the Sensitivity of Gold Nanoparticle
    sensors Letter Effect of Thiol Molecular Structure on the Sensitivity of Gold Nanoparticle-Based Chemiresistors toward Carbonyl Compounds 1, 2, 3 Zhenzhen Xie y, Mandapati V. Ramakrishnam Raju y, Prasadanie K. Adhihetty , Xiao-An Fu 1 and Michael H. Nantz 3,* 1 Department of Chemical Engineering, University of Louisville, Louisville, KY 40208, USA; [email protected] (Z.X.); [email protected] (X.-A.F.) 2 Department of Chemistry, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] 3 Department of Chemistry, University of Louisville, Louisville, KY 40208, USA; [email protected] * Correspondence: [email protected] These authors contributed equally. y Received: 2 November 2020; Accepted: 4 December 2020; Published: 8 December 2020 Abstract: Increasing both the sensitivity and selectivity of thiol-functionalized gold nanoparticle chemiresistors remains a challenging issue in the quest to develop real-time gas sensors. The effects of thiol molecular structure on such sensor properties are not well understood. This study investigates the effects of steric as well as electronic effects in a panel of substituted thiol-urea compounds on the sensing properties of thiolate monolayer-protected gold nanoparticle chemiresistors. Three series of urea-substituted thiols with different peripheral end groups were synthesized for the study and used to prepare gold nanoparticle-based chemiresistors. The responses of the prepared sensors to trace volatile analytes were significantly affected by the urea functional motifs. The largest response for sensing acetone among the three series was observed for the thiol-urea sensor featuring a tert-butyl end group. Furthermore, the ligands fitted with N, N’-dialkyl urea moieties exhibit a much larger response to carbonyl analytes than the more acidic urea series containing N-alkoxy-N’-alkyl urea and N, N’-dialkoxy urea groups with the same peripheral end groups.
    [Show full text]
  • Poly(Urea Ester): a Family of Biodegradable Polymers with High Melting Temperatures
    JOURNAL OF POLYMER SCIENCE WWW.POLYMERCHEMISTRY.ORG RAPID COMMUNICATION Poly(Urea Ester): A Family of Biodegradable Polymers with High Melting Temperatures Donglin Tang,1 Zijian Chen,1 Felipe Correa-Netto,2 Christopher W. Macosko,2 Marc A. Hillmyer,3 Guangzhao Zhang1 1School of Materials Science and Engineering, South China University of Technology, Guangzhou, 510640, People’s Republic of China 2Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota, 55455-0431 3Department of Chemistry, University of Minnesota, Minneapolis, Minnesota, 55455-0431 Correspondence to: D. Tang (E-mail: [email protected]) Received 10 August 2016; accepted 2 September 2016; published online 20 September 2016 DOI: 10.1002/pola.28355 KEYWORDS: biodegradable; polycondensation; poly(urea ester); TBD; transesterification As one of the environmental problems, ‘white pollution’ is performance. Mulhaupt and co-workers reported previously caused by the accumulation of nondegradable polymer materi- the preparation of PUEs based on polyether polyols through als. Recycling is one solution, however, creating biodegradable an N,N0-carbonylbiscaprolactam route but only crosslinked polymers would be more feasible for many applications.1–6 If materials were prepared.23 Du et al. also synthesized nonbio- those biodegradable polymers exhibit similar properties to the degradable liquid crystalline PUEs.24 To the best of our nonbiodegradable ones then they should be more commercial- knowledge, this work would be the first one
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Ammonia and Urea Production
    Ammonia and urea production: Incidents of ammonia release from the Profertil urea and ammonia facility, Bahia Blanca, Argentina 2000. Brigden, K. & Stringer, R. Greenpeace Research Laboratories, Department of Biological Sciences, University of Exeter, Exeter, UK. December 2000 Technical Note: 17/00 TABLE OF CONTENTS The Profertil facility ......................................................................................................... 3 1. Introduction ................................................................................................................ 4 1.1 Fertilizers.............................................................................................................. 4 1.2 Ammonia .............................................................................................................. 4 1.3 Urea...................................................................................................................... 5 2. Production ................................................................................................................ 5 2.1 Ammonia .............................................................................................................. 5 2.1.1 Emissions....................................................................................................... 6 2.1.2 Storage........................................................................................................... 6 2.2 Urea.....................................................................................................................
    [Show full text]
  • Novel Phenyl-Urea Derivatives As Dual-Target Ligands That Can Activate Both GK and Pparc
    Acta Pharmaceutica Sinica B 2012;2(6):588–597 Institute of Materia Medica, Chinese Academy of Medical Sciences Chinese Pharmaceutical Association Acta Pharmaceutica Sinica B www.elsevier.com/locate/apsb www.sciencedirect.com ORIGINAL ARTICLE Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARc Lijian Zhanga,y, Kang Tiana,y, Yongqiang Lib,y, Lei Leic, Aifang Qina, Lijuan Zhanga, Hongrui Songa, Lianchao Huob, Lijing Zhangb, Xiaofeng Jinb, Zhufang Shenc, Zhiqiang Fengb,n aSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China bInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China cBeijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China Received 29 May 2012; revised 20 September 2012; accepted 9 October 2012 KEY WORDS Abstract A series of novel phenyl-urea derivatives which can simultaneously activate glucokinase (GK) and peroxisome proliferator-activated receptor g (PPARg) was designed and prepared, and Type 2 diabetes; GK activators; their activation of GK and PPARg was evaluated. The structure–activity relationships of these PPARg agonists; compounds are also described. Three compounds showed potent ability to activate both GK and Dual action PPARg. The possible binding mode of one of these compounds with GK and PPARg were predicted by molecular docking simulation. & 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and hosting by Elsevier B.V. All rights reserved. nCorresponding author. Tel.: þ86 10 63189351. E-mail address: [email protected] (Zhiqiang Feng).
    [Show full text]